Story perspectives

Isomorphic Labs Secures $2.1B Series B for AI Drug Design

5/13/2026

Summary

Isomorphic Labs Secures

Isomorphic Labs secured $2.1 billion in Series B funding led by Thrive Capital and backed by Alphabet and UK Sovereign AI Fund.
Founder and CEO Sir Demis Hassabis and President Max Jaderberg said the financing validates the AI-first drug design approach and will scale the IsoDDE engine toward trials.
The money will fund hiring AI, engineering, drug-design and talent in London, Cambridge and Massachusetts, and support partnerships with Novartis, Lilly and Johnson & Johnson.

Summary

Isomorphic Labs Delays

Isomorphic Labs now expects its first AI-designed drugs to begin trials by end-2026, delaying the late-2025 target.
The firm secured $2.1 billion as competition intensifies among companies using generative AI for drug discovery, after breakthroughs such as AlphaFold that predict protein structures accurately.
IsoDDE unifies protein-structure prediction, molecular-interaction modeling and binding-affinity analysis in one AI engine.
Analysts say the funding signals a global surge of capital into AI-driven healthcare infrastructure.

Summary

IsoDDE Funding

IsoDDE secured a $2.1 billion funding round with investors from the United States, Middle East, Southeast Asia and Europe.
The financing will drive a hiring surge for rare talent that blends machine-learning and medicinal-chemistry expertise across London, Cambridge, Massachusetts and Lausanne.
IsoDDE’s proprietary model more than doubled AlphaFold 3’s accuracy on the hardest Runs N’ Poses cases, achieving roughly 76% versus AlphaFold 3’s 48% on antibody-antigen interfaces.

History

Historical Context

DeepMind’s AlphaFold first won CASP13 in December 2018, and AlphaFold 2 achieved a median 92.4 % GDT score at CASP14 in November 2020, earning a Nobel Prize for Demis Hassabis and John Jumper in 2024. The landmark results have opened pathways for AI-driven therapeutics and have inspired new biotech ventures with clinical trials planned by 2026.

1 of 4

Isomorphic Labs Secures

Isomorphic Labs secured $2.1 billion in Series B funding led by Thrive Capital and backed by Alphabet and UK Sovereign AI Fund.
Founder and CEO Sir Demis Hassabis and President Max Jaderberg said the financing validates the AI-first drug design approach and will scale the IsoDDE engine toward trials.
The money will fund hiring AI, engineering, drug-design and talent in London, Cambridge and Massachusetts, and support partnerships with Novartis, Lilly and Johnson & Johnson.

1 / 4